Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01465230 · ClinicalTrials.gov registry record · Phase 2
Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia
A Phase 2 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01465230 is a Phase 2 study that was terminated before completion, run by Yale University. The registered enrollment target is 2 participants.
The verdict
NCT01465230, a Phase 2 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study will determine whether or not Lenalidomide improves effectiveness of treatment for chronic lymphocytic leukemia following chemotherapy with two drugs commonly used to treat the disease (bendamustine and rituximab).
Interventions
- DRUG Maintenance lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01465230
The ClinicalTrials.gov registry entry for NCT01465230 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Maintenance lenalidomide is the first listed.
NCT01465230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01465230 about?
NCT01465230 is a clinical study titled "Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia". This study will determine whether or not Lenalidomide improves effectiveness of treatment for chronic lymphocytic leukemia following chemotherapy with two drugs commonly used to treat the disease (bendamustine and rituximab).
What is the current status of trial NCT01465230?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2012-03. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01465230?
The interventions under investigation include: Maintenance lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01465230?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.